CrossrefInfokarte
Development of both type I–B and type II CRISPR/Cas genome editing systems in the cellulolytic bacterium Clostridium thermocellum
Metabolic Engineering Communications · 2020-06 · 10 · e00116
DOI: 10.1016/j.mec.2019.e00116 ↗Abstract
Kein Abstract verfügbar.
EUVIMED